Phase II and biomarker study of programmed cell death protein 1 inhibitor nivolumab and metronomic cyclophosphamide in paediatric relapsed/refractory solid tumours: Arm G of AcSe-ESMART, a trial of the European Innovative Therapies for Children With Cancer Consortium

Pasqualini Claudia; Rubino Jonathan; Brard Caroline; Cassard Lydie; Andre Nicolas; Rondof Windy; Scoazec Jean-Yves; Marchais Antonin; Nebchi Souad; Boselli Lisa; Grivel Jonathan; Aerts Isabelle; Thebaud Estelle; Paoletti Xavier; Minard-Colin Veronique; Vassal Gilles; Geoerger Birgit

首页> 外文期刊>European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) >Phase II and biomarker study of programmed cell death protein 1 inhibitor nivolumab and metronomic cyclophosphamide in paediatric relapsed/refractory solid tumours: Arm G of AcSe-ESMART, a trial of the European Innovative Therapies for Children With Cancer Consortium

【24h】

Phase II and biomarker study of programmed cell death protein 1 inhibitor nivolumab and metronomic cyclophosphamide in paediatric relapsed/refractory solid tumours: Arm G of AcSe-ESMART, a trial of the European Innovative Therapies for Children With Cancer Consortium

机译：编程性细胞死亡蛋白1抑制剂Nivolumab和难以解决的固体瘤中抑制剂Nivolumab和核心环磷酰胺的II和生物标志物研究：ARM G ACSE-ESMART，欧洲癌症联盟儿童的欧洲创新疗法的试验

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Purpose: AcSe-ESMART is a European multicentre, proof-of-concept multiarm phase I/II platform trial in paediatric patients with relapsed/refractory cancer. Arm G assessed the activity and safety of nivolumab in combination with metronomic cyclophosphamide +/- irradiation.

机译：None

著录项

来源
《European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)》 |2021年第1期|共10页
作者
Pasqualini Claudia; Rubino Jonathan; Brard Caroline; Cassard Lydie; Andre Nicolas; Rondof Windy; Scoazec Jean-Yves; Marchais Antonin; Nebchi Souad; Boselli Lisa; Grivel Jonathan; Aerts Isabelle; Thebaud Estelle; Paoletti Xavier; Minard-Colin Veronique; Vassal Gilles; Geoerger Birgit;
展开▼
作者单位

Univ Paris Saclay Dept Pediat &

Adolescent Oncol Gustave Roussy Canc Campus Villejuif France;

Univ Paris Saclay Gustave Roussy Canc Campus Clin Res Direct Villejuif France;

Univ Paris Saclay Biostat &

Epidemiol Unit Gustave Roussy Canc Campus CESP INSERM U1018;

Univ Paris Saclay Gustave Roussy Canc Campus Lab Immune Monitoring Oncol Villejuif France;

Hop La Timone AP HM Dept Pediat Oncol Marseille France;

Univ Paris Saclay Gustave Roussy Canc Campus INSERM U1015 Villejuif France;

Univ Paris Saclay Dept Med Biol &

Pathol Translat Res &

Biobank Gustave Roussy Canc Campus;

Univ Paris Saclay Gustave Roussy Canc Campus INSERM U1015 Villejuif France;

Univ Paris Saclay Biostat &

Epidemiol Unit Gustave Roussy Canc Campus CESP INSERM U1018;

Univ Paris Saclay Gustave Roussy Canc Campus Lab Immune Monitoring Oncol Villejuif France;

Univ Paris Saclay Gustave Roussy Canc Campus Lab Immune Monitoring Oncol Villejuif France;

PSL Res Univ Inst Curie Care Innovat &

Res Children &

AYA Canc SIREDO Oncol Ctr Paris France;

CHU Nantes Dept Pediat Oncol Nantes France;

Univ Paris Saclay Biostat &

Epidemiol Unit Gustave Roussy Canc Campus CESP INSERM U1018;

Univ Paris Saclay Dept Pediat &

Adolescent Oncol Gustave Roussy Canc Campus Villejuif France;

Univ Paris Saclay Gustave Roussy Canc Campus Clin Res Direct Villejuif France;

Univ Paris Saclay Dept Pediat &

Adolescent Oncol Gustave Roussy Canc Campus Villejuif France;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词
Paediatric cancers; Immune checkpoint inhibitor; Tumour microenvironment; Immune monitoring; Phase 2 clinical trial;

机译：儿科癌症;免疫检查点抑制剂;肿瘤微环境;免疫监测;第2期临床试验;

相似文献

外文文献
中文文献

1. Phase II study of gemcitabine combined with oxaliplatin in relapsed or refractory paediatric solid malignancies: An innovative therapy for children with Cancer European Consortium Study. [J] . Geoerger B, Chisholm J, Le Deley MC, European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2011,第2期

机译：吉西他滨联合奥沙利铂治疗复发性或难治性小儿实体恶性肿瘤的II期研究：针对癌症的儿童的创新疗法欧洲联合体研究。
2. Phase II results from a phase I/II study to assess the safety and efficacy of weekly nab-paclitaxel in paediatric patients with recurrent or refractory solid tumours: A collaboration with the European Innovative Therapies for Children with Cancer Network [J] . Amoroso Loredana, Castel Victoria, Bisogno Gianni, European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2020,第1期

机译：II期结果来自I / II期的研究，以评估每周Nab-紫杉醇在儿科患者中进行复发或难治性固体瘤的安全性和功效：与癌症网络儿童的欧洲创新疗法合作
3. Phase I results of a phase I/II study of weekly nab-paclitaxel in paediatric patients with recurrent/refractory solid tumours: A collaboration with innovative therapies for children with cancer [J] . Moreno Lucas, Casanova Michela, Chisholm Julia C., European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2018,第期

机译：I期I / II研究每周Nab-紫杉醇在儿科患者中进行复发/难治性固体瘤的研究：与癌症儿童的创新疗法合作
4. A Phase 1 Study of the c-Met Inhibitor Tivantinib (ARQ197) in Children with Relapsed or Refractory Solid Tumors: A Children’s Oncology Group Study Phase 1 and Pilot Consortium Trial (ADVL1111) [O] . James I. Geller, John P. Perentesis, Xiaowei Liu, -1

机译：c-Met抑制剂Tivantinib（ARQ197）在患有复发性或难治性实体瘤的儿童中进行的1期研究：儿童肿瘤学小组研究1期和试验性联合试验（ADVL1111）
5. Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1–2 trial [O] . Kara L Davis, Elizabeth Fox, Melinda S Merchant, 2020

机译：儿童和年轻成年人的Nivolumab复发或难治性实体肿瘤或淋巴瘤（ADVL 1412）：多中心，开放标签，单臂，第1-2期试验

Phase II and biomarker study of programmed cell death protein 1 inhibitor nivolumab and metronomic cyclophosphamide in paediatric relapsed/refractory solid tumours: Arm G of AcSe-ESMART, a trial of the European Innovative Therapies for Children With Cancer Consortium

摘要

著录项

相似文献

相关主题

期刊订阅